MyMD Pharmaceuticals, Inc.

Two Broad Drug Platforms: MYMD-1 and Supera-CBD

MYMD-1

MYMD-1 is a small molecule, synthetic plant alkaloid, that is undergoing clinical trials for the treatment of Sarcopenia, Immune-Mediated Depression, Multiple Sclerosis, Rheumatoid Arthritis, and Type 2 Diabetes. MYMD-1 targets the immune system as an immunometabolic regulator by inhibiting the release of pro-inflammatory cytokines, which are molecules that are involved in the proper coordination of the body’s immune system.

Inflammation, which occurs when cytokines are released into the body, is the normal physiological defense against pathogens or infection. Typically, this inflammation resolves once the body naturally identifies and addresses the issue. However, these pro-inflammatory cytokines are sometimes released at elevated levels beyond what is necessary. When this occurs, it leads to prolonged chronic inflammation, which is linked to autoimmune diseases, aging, cardiovascular disease, and even cancer.

MYMD-1 has shown effectiveness in regulating the release of multiple cytokines, including TNF-α. While there are various TNF-α blocking drugs already on the market, they must be injected or infused to work, and they are non-selective so they can cause serious viral, bacterial, and fungal infections. To avoid these concerning side effects, MYMD-1 is being developed as an orally administered, selective TNF-α inhibitor. Beyond the therapeutic potential of MYMD-1, there is also substantial financial potential, with the global market for TNF-α blockers expected to reach $45.5 billion by 2027.

Supera-CBD

Supera-CBD is a synthetic cannabidiol analog of the Cannabis sativa plant, whose developmental intention is to treat CBD-associated conditions that have no current synthetic or natural CBD-based drugs approved by the FDA. Supera-CBD has shown indications of improved bioavailability and increased potency compared to botanical CBD products.

CBD inhibits many important cell receptors in the body, including the CB2 receptor, which plays a key role in regulating cytokine released from immune cells. Based on this understanding, CB2-inhibiting drugs like Supera-CBD have been proposed to treat many painful conditions and some neurological diseases where mis-regulated cytokine levels are a key driver.

Supera-CBD has also shown potential in other areas of therapeutic need, like playing a role in opioid addiction by inhibiting opioid receptors or treating depression and age-related cognitive decline by inhibiting MAO enzymes. Currently, there are many over-the-counter CBD products, but only one FDA-approved drug based on CBD. By going through the rigors of obtaining FDA approval, MyMD intends for Supera-CBD to have a competitive advantage over non-FDA approved CBD drugs to secure a major position in the US CBD market that is projected to reach $19.5 billion by 2025.

Operational breakdown

MyMD Pharmaceuticals has a limited operating history and has primarily been occupied with business planning, capital raising, and conducting research and development activities for its two product platforms. Although MYMD-1 is making progress through clinical trials for multiple disease indications, the company has yet to obtain any regulatory approval and therefore has generated no revenue from product sales. MyMD has so far funded its operations solely through the proceeds of common stock and a line of credit from an affiliate of the company’s founder.

If MyMD Pharmaceuticals does eventually generate revenue from product sales, agreement milestones or sub-license compensation, the company has an obligation in place to pay 8% in royalties to SRQ Patent Holdings or SRQ Patent Holdings II. These are affiliates of the company’s founder, Jonnie R. Williams Sr., who developed MyMD’s patent position for MYMD-1 through SRQ Patent Holdings and Supera-CBD through SRQ Patent Holdings II. Although a fairly sizable portion of future revenue is already accounted for through these royalties, MyMD fully owns the rights and intellectual property for the two platforms, including 15 active US patents and 28 pending patents internationally.

MyMD Pharmaceuticals only has nine employees, of which six are primarily involved in research in development on the two platforms and who also oversee the third-party contractors and consultants the company hires to assist with research and development activities.

Conclusion

Both MYMD-1 and Supera-CBD are product platforms that have far-reaching medical potential with the ability to improve life circumstances and increase longevity. Beyond just treating the symptoms, MyMD’s product candidates are poised to provide life-changing therapeutic solutions that address disease and decline at the root cause. Given that the company boasts two high-potential platforms that cover a broad area of medical need, it wouldn’t be surprising to see MyMD therapies reach market in at least some capacity.